Navigation Links
BioElectronics Corporation Announces Initiative for UK and German Markets
Date:7/12/2012

FREDERICK, Md., July 12, 2012 /PRNewswire/ -- BioElectronics Corporation ("BioElectronics") (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, today announced the formation of ActiPatch Plc, an entity through which BioElectronics proposes to conduct all sales, marketing, advertising and distribution functions for BioElectronics' medical devices in the German (81.3 million people) and United Kingdom (60 million people) markets.  BioElectronics will manage the operations of ActiPatch Plc, which will focus on promoting Allay for menstrual pain and the ActiPatch products for musculoskeletal pain.

"The German and UK markets are ideal markets for sustained direct to consumer advertising campaigns for our home use pain devices," said Andrew Whelan, CEO and President, BioElectronics.  Menstrual pain affects nearly 50% of women capable of reproducing and a recent EU Commission study suggests that 14.2 million people in Germany and 9.6 million in the UK suffered pain in their lower or upper back in the previous week.  BioElectronics' products have broad market clearances in the EU and UK where shortwave therapy is well understood and widely used by medical professionals.

"We have engaged a London-based team to put together the new company and coordinate the proposed PLUS-quoted application process," Mr. Whelan said.  The Corporate Adviser, SVS Securities Plc, is leading the team which includes the accounting firm, Bennett Brooks & Co, Ltd. and the law firm of Irvine and Partners.

About SVS Securities Plc
SVS Securities Plc (www.svssecurities.com) focuses on advising and assisting small to mid-sized companies in growth markets who may seek to raise funds.

About BioElectronics Corporation
BioElectronics is a developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care method to reduce soft tissue pain and swelling. The Company also manufactures HealFast™ Therapy (http://www.healfasttherapy.com) which is sold by eMarkets Group.  For more information, please visit www.bielcorp.com.

For media inquiries, please contact:

Paul Knopick
940.262.3584
pknopick@eandecommunications.com
E&E Communications


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Corporation Announces Indian Distributors Ecommerce Website
2. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
3. BioElectronics ActiPatch Reduces Muscle Soreness in Runners
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
6. Luminex Corporation Announces Agreement to Acquire GenturaDx
7. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
8. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
9. Celladon Corporation Receives Notice of Allowance from European Patent Office
10. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
11. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):